Medication info

Gentapro Injection (Gentamicin Sulfate)

Prescription medication
Ingredient · strength
Gentamicin Sulfate›40mg / 1mL
Manufacturer / importer
Humedics Co., Ltd.
Appearance
Colorless, odorless transparent liquid
Packaging
50 ampoules/box [(2 milliliters/ampoule)]
Approval status
Active

MFDS item code 199600433 · Notified 1996.10.22 · Insurance code 683100121

Summary

Main use
Treatment and prevention of bacterial infections (e.g., sepsis), eye and skin infections, and bone and soft-tissue infections
Who uses it
Adults · Children
Adult dosage
(Injection) 1. Patients with normal renal function The usual duration of treatment is 7~10 days; it may be extended in severe or refractory cases. 1) Adults: Administer 3mg (potency)/Kg of body weight per day as gentamicin in divided doses by intravenous or intramuscular injection every 8 hours. In life-threatening cases, administer 5mg (potency)/Kg of body weight per day in 3~4 divided doses. Reduce the dose as symptoms improve. At this time, it is desirable that the peak serum concentration not exceed 12㎍/mL and the trough serum concentration (immediately before the next dose) not exceed 2㎍/mL. <Table 1> Body weight (Kg) / Usual dose for severe infection (1mg/Kg every 8 hours) / Dose for life-threatening cases (1.7mg/Kg every 8 hours) 40 / 1.0mL(40mg) / 1.6mL(66mg) 45 / 1.1mL(45mg) / 1.9mL(75mg) 50 / 1.25mL(50mg) / 2.1mL(83mg) 55 / 1.4mL(55mg) / 2.25mL(91mg) 60 / 1.5mL(60mg) / 2.5mL(100mg) 65 / 1.6mL(65mg) / 2.7mL(108mg) 70 / 1.75mL(70mg) / 2.9mL(116mg) 75 / 1.9mL(75mg) / 3.1mL(125mg) 80 / 2.0mL(80mg) / 3.3mL(133mg) 85 / 2.1mL(85mg) / 3.5mL(141mg) 90 / 2.25mL(90mg) / 3.75mL(150mg) 95 / 2.4mL(95mg) / 4.0mL(158mg) 100 / 2.5mL(100mg) / 4.2mL(166mg) ※ Intravenous injection Administer intravenously to patients for whom intramuscular injection is inappropriate, such as patients with sepsis, shock, congestive heart failure, hematologic disorders, severe burns, or decreased muscle mass. The amount injected is the same as for intramuscular injection, but dilute it as follows and administer separately without mixing it with other drugs. For intermittent intravenous injection, dilute a single dose in 50~200mL of normal saline injection or 5% dextrose injection and administer by intravenous infusion over 30 minutes~2 hours. 2. Patients with renal impairment 1) Adjust the dose in patients with renal impairment according to the degree of renal impairment. <Table 2> Dose adjustment in patients with renal impairment (dose at 8-hour intervals after the initial dose) Serum creatinine (mg %) / Approximate creatinine clearance (mL/min/1.73㎡) / Percentage of the dose for patients with normal renal function ≤ 1.0 / > 100 / 100 1.1 - 1.3 / 70 - 100 / 80 1.4 - 1.6 / 55 - 70 / 65 1.7 - 1.9 / 45 - 55 / 55 2.0 - 2.2 / 40 - 45 / 50 2.3 - 2.5 / 35 - 40 / 40 2.6 - 3.0 / 30 - 35 / 35 3.1 - 3.5 / 25 - 30 / 30 3.6 - 4.0 / 20 - 25 / 25 4.1 - 5.1 / 15 - 20 / 20 5.2 - 6.6 / 10 - 15 / 15 6.7 - 8.0 / < 10 / 10 Since the serum half-life of gentamicin is closely related to the serum creatinine concentration, the dosing interval can be estimated approximately by multiplying the serum creatinine concentration (mg/100mL) by 8. 2) Patients with renal impairment and severe systemic infection: It is preferable to reduce the dose and increase the frequency of administration. Serum gentamicin concentrations must be monitored in these patients to adjust the dose. Administer the usual dose for patients with normal renal function as the initial dose, and approximately calculate subsequent doses (administered every 8 hours) by dividing the normally recommended dose by the serum creatinine concentration. 3. Urinary tract infections For urinary tract infections in patients with normal renal function, 160mg (potency) may be administered once daily. Adjust the dose as appropriate according to age and symptoms. (Ophthalmic solution) Instill 1~2 drops into the affected area every 4 hours. In severe cases, instill 2 drops every hour. Adjust the dose as appropriate according to age and symptoms. (Ointment)(Cream) Apply to the affected area 1~4 times daily and rub in gently. Gauze may be applied if necessary. For contagious impetigo, it is preferable to remove the crusts (scabs) before application to maximize contact between this drug and the infected area. Remove them carefully to avoid contaminating other areas of normal skin. (Implant) - This drug is completely absorbed, so it does not need to be removed separately. - Implants remaining after use during surgery cannot be sterilized; do not reuse them and discard them. - One 10x10cm implant is equivalent to four 5x5cm implants. - Unless otherwise instructed, use as follows, taking care not to press the implant firmly. 1. After surgical treatment of the site of infection, use 1~3 10x10cm implants for patients weighing 50Kg or less, and up to 5 10x10cm implants for patients weighing 50Kg or more, according to the size of the site. For small wounds, cut the implant or use a 5x5cm implant. 2. For cancellous bone grafting or cementless artificial joint implantation, use 1~3 10x10cm implants in patients weighing 50Kg or less, and up to 5 in patients weighing 50Kg or more. 3. For soft tissue infection after surgical treatment of the site of infection, up to 3 10x10cm implants may be used according to the size of the site. If the site is small, cut the implant to the appropriate size or use a 5x5cm implant.
Children's dosage
(Injection) Children: Administer 6~7.5mg/kg of body weight daily (potency) by intravenous or intramuscular injection in divided doses every 8 hours. Infants: Administer 7.5mg/kg of body weight daily (potency) by intravenous or intramuscular injection in divided doses every 8 hours. Premature infants and neonates under 1 week of age: Administer 5mg/kg of body weight daily (potency) by intravenous injection in divided doses every 12 hours. The safety of intravenous drip infusion has not been established in premature infants, neonates, infants, or children. The safety of intramuscular injection has not been established in premature infants or neonates. For infants and children, adjust the amount of diluent appropriately. For pediatric patients receiving hemodialysis, administer 2mg/kg of body weight (potency) at the end of each dialysis session.

Ingredients

Manufacturer
Humedics Co., Ltd.

Efficacy & effects

Treatment and prevention of bacterial infections (e.g., sepsis), eye and skin infections, and bone and soft-tissue infections

  • Sepsis
  • central nervous system infections
  • urinary tract infections
  • respiratory infections
  • gastrointestinal infections
  • skin infections
  • bone infections
  • soft tissue infections
  • conjunctivitis
  • keratitis
  • blepharitis
  • dacryocystitis
View approved original text

This injection is used for the treatment of various infections caused by several bacteria including Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus. It is effective for sepsis, central nervous system infections, urinary tract infections, respiratory infections, gastrointestinal infections, skin infections, bone and soft tissue infections. It is particularly used for the initial treatment of gram-negative bacterial infections, when the causative agent is unclear, and in cases of life-threatening Pseudomonas aeruginosa infections. Additionally, it is used in combination for the treatment of endocarditis, which can be administered alongside penicillin-type drugs. The eye drops are used for the treatment of infections around the eyes such as conjunctivitis and keratitis, while the ointments and creams are effective for contagious subcutaneous infections and secondary skin infections. The grafts are used to prevent and treat infections after osteomyelitis or artificial joint implantation. Overall, this drug is widely used for the treatment of various bacterial infections.

Dosage and Administration

Adult dosage

(Injection) 1. Patients with normal renal function The usual duration of treatment is 7~10 days; it may be extended in severe or refractory cases. 1) Adults: Administer 3mg (potency)/Kg of body weight per day as gentamicin in divided doses by intravenous or intramuscular injection every 8 hours. In life-threatening cases, administer 5mg (potency)/Kg of body weight per day in 3~4 divided doses. Reduce the dose as symptoms improve. At this time, it is desirable that the peak serum concentration not exceed 12㎍/mL and the trough serum concentration (immediately before the next dose) not exceed 2㎍/mL. <Table 1> Body weight (Kg) / Usual dose for severe infection (1mg/Kg every 8 hours) / Dose for life-threatening cases (1.7mg/Kg every 8 hours) 40 / 1.0mL(40mg) / 1.6mL(66mg) 45 / 1.1mL(45mg) / 1.9mL(75mg) 50 / 1.25mL(50mg) / 2.1mL(83mg) 55 / 1.4mL(55mg) / 2.25mL(91mg) 60 / 1.5mL(60mg) / 2.5mL(100mg) 65 / 1.6mL(65mg) / 2.7mL(108mg) 70 / 1.75mL(70mg) / 2.9mL(116mg) 75 / 1.9mL(75mg) / 3.1mL(125mg) 80 / 2.0mL(80mg) / 3.3mL(133mg) 85 / 2.1mL(85mg) / 3.5mL(141mg) 90 / 2.25mL(90mg) / 3.75mL(150mg) 95 / 2.4mL(95mg) / 4.0mL(158mg) 100 / 2.5mL(100mg) / 4.2mL(166mg) ※ Intravenous injection Administer intravenously to patients for whom intramuscular injection is inappropriate, such as patients with sepsis, shock, congestive heart failure, hematologic disorders, severe burns, or decreased muscle mass. The amount injected is the same as for intramuscular injection, but dilute it as follows and administer separately without mixing it with other drugs. For intermittent intravenous injection, dilute a single dose in 50~200mL of normal saline injection or 5% dextrose injection and administer by intravenous infusion over 30 minutes~2 hours. 2. Patients with renal impairment 1) Adjust the dose in patients with renal impairment according to the degree of renal impairment. <Table 2> Dose adjustment in patients with renal impairment (dose at 8-hour intervals after the initial dose) Serum creatinine (mg %) / Approximate creatinine clearance (mL/min/1.73㎡) / Percentage of the dose for patients with normal renal function ≤ 1.0 / > 100 / 100 1.1 - 1.3 / 70 - 100 / 80 1.4 - 1.6 / 55 - 70 / 65 1.7 - 1.9 / 45 - 55 / 55 2.0 - 2.2 / 40 - 45 / 50 2.3 - 2.5 / 35 - 40 / 40 2.6 - 3.0 / 30 - 35 / 35 3.1 - 3.5 / 25 - 30 / 30 3.6 - 4.0 / 20 - 25 / 25 4.1 - 5.1 / 15 - 20 / 20 5.2 - 6.6 / 10 - 15 / 15 6.7 - 8.0 / < 10 / 10 Since the serum half-life of gentamicin is closely related to the serum creatinine concentration, the dosing interval can be estimated approximately by multiplying the serum creatinine concentration (mg/100mL) by 8. 2) Patients with renal impairment and severe systemic infection: It is preferable to reduce the dose and increase the frequency of administration. Serum gentamicin concentrations must be monitored in these patients to adjust the dose. Administer the usual dose for patients with normal renal function as the initial dose, and approximately calculate subsequent doses (administered every 8 hours) by dividing the normally recommended dose by the serum creatinine concentration. 3. Urinary tract infections For urinary tract infections in patients with normal renal function, 160mg (potency) may be administered once daily. Adjust the dose as appropriate according to age and symptoms. (Ophthalmic solution) Instill 1~2 drops into the affected area every 4 hours. In severe cases, instill 2 drops every hour. Adjust the dose as appropriate according to age and symptoms. (Ointment)(Cream) Apply to the affected area 1~4 times daily and rub in gently. Gauze may be applied if necessary. For contagious impetigo, it is preferable to remove the crusts (scabs) before application to maximize contact between this drug and the infected area. Remove them carefully to avoid contaminating other areas of normal skin. (Implant) - This drug is completely absorbed, so it does not need to be removed separately. - Implants remaining after use during surgery cannot be sterilized; do not reuse them and discard them. - One 10x10cm implant is equivalent to four 5x5cm implants. - Unless otherwise instructed, use as follows, taking care not to press the implant firmly. 1. After surgical treatment of the site of infection, use 1~3 10x10cm implants for patients weighing 50Kg or less, and up to 5 10x10cm implants for patients weighing 50Kg or more, according to the size of the site. For small wounds, cut the implant or use a 5x5cm implant. 2. For cancellous bone grafting or cementless artificial joint implantation, use 1~3 10x10cm implants in patients weighing 50Kg or less, and up to 5 in patients weighing 50Kg or more. 3. For soft tissue infection after surgical treatment of the site of infection, up to 3 10x10cm implants may be used according to the size of the site. If the site is small, cut the implant to the appropriate size or use a 5x5cm implant.

Children's dosage

(Injection) Children: Administer 6~7.5mg/kg of body weight daily (potency) by intravenous or intramuscular injection in divided doses every 8 hours. Infants: Administer 7.5mg/kg of body weight daily (potency) by intravenous or intramuscular injection in divided doses every 8 hours. Premature infants and neonates under 1 week of age: Administer 5mg/kg of body weight daily (potency) by intravenous injection in divided doses every 12 hours. The safety of intravenous drip infusion has not been established in premature infants, neonates, infants, or children. The safety of intramuscular injection has not been established in premature infants or neonates. For infants and children, adjust the amount of diluent appropriately. For pediatric patients receiving hemodialysis, administer 2mg/kg of body weight (potency) at the end of each dialysis session.

Precautions

Care must be taken when handling this medication as glass fragments may be mixed in if the ampoule is broken. Extra caution is needed, especially for children and the elderly. This medication should not be used if there is an allergy to this drug or similar antibiotics, or if the patient is pregnant or breastfeeding. Patients with hearing impairment or kidney dysfunction, neonates, premature infants, elderly patients, or those with muscle disorders should use this drug with caution. It may cause allergic reactions or asthma attacks, so asthmatic patients should be particularly careful. If any abnormal symptoms occur during administration, such as shock, rash, itching, hearing loss, dizziness, vomiting, or respiratory distress, the use should be immediately discontinued, and a doctor should be consulted. Regular kidney and liver function tests should be performed, and the dosage should be adjusted as necessary. Prolonged use may lead to vitamin deficiency symptoms, so attention is needed. When used in combination with other drugs that may affect the kidneys or muscle relaxants, the risk of side effects increases, so it is advisable to consult a doctor. Pregnant or breastfeeding women should refrain from using this drug or use it cautiously based on medical judgment. Dosages and administration intervals should be adjusted for children or the elderly based on their physical condition, and particularly careful considerations should be taken if kidney function is impaired. In case of overdose, serious side effects such as kidney damage, hearing loss, or respiratory paralysis may occur, necessitating immediate emergency care. Pain or induration at the injection site may occur, so it is advisable to massage the area well after injection. When using this drug as eye drops or ointments, allergic reactions or local irritation symptoms may occur, so caution is advised, and the safety for children under 6 years of age has not been established. This medication should only be used for the prescribed duration to prevent bacterial resistance, and prolonged use may lead to new infections or side effects, so discontinuation and consultation with a doctor are necessary. Finally, it is crucial to keep this medicine out of reach of children and adhere to the usage period.

Side effects

  • Shivering
  • cyanosis
  • shortness of breath
  • chest discomfort
  • hypotension
  • itching
  • rash
  • fever
  • dizziness
  • tinnitus
Show 68 more
  • hearing loss
  • loss of hearing
  • ataxia
  • numbness in limbs
  • hallucinations
  • delusions
  • convulsions
  • altered consciousness
  • headache
  • drowsiness
  • depression
  • vision impairment
  • skin tingling
  • muscle cramps
  • vomiting
  • loss of appetite
  • excessive salivation
  • stomatitis
  • nausea
  • laryngeal edema
  • pulmonary fibromatosis
  • eosinophilia
  • leukopenia
  • agranulocytosis
  • changes in reticulocyte count
  • thrombocytopenia
  • anemia
  • granulocytopenia
  • hepatic dysfunction
  • acute kidney failure
  • edema
  • oliguria
  • elevated BUN
  • decreased creatinine clearance
  • proteinuria
  • abnormal uric acid levels
  • hematuria
  • electrolyte imbalance
  • hypoprothrombinemia
  • tendency to bleed
  • glossitis
  • neuritis
  • injection site pain
  • injection site induration
  • excessive growth of resistant bacteria
  • hypertension
  • hypotension
  • alopecia areata
  • weight loss
  • anaphylactic reaction
  • allergic conjunctivitis
  • allergic blepharitis
  • contact dermatitis
  • burning sensation
  • conjunctival edema
  • irritation
  • pain
  • congestion
  • lifespan
  • foreign body sensation
  • thrombocytopenic purpura
  • hallucinations
  • contact dermatitis
  • localized erythema
  • cylinders in urine
  • presence of cells or protein
  • increased urinary frequency
  • decreased urination

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture ingress and should be kept in a cool room at room temperature, away from direct sunlight.

Appearance and packaging

Appearance

Colorless, odorless transparent liquid

Package unit

50 ampoules/box [(2 milliliters/ampoule)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.